This site is intended for healthcare professionals
eLearning

CDK4/6 inhibitor selection eLearning

Read time: 25 mins
Last updated:11th Oct 2022
Published:3rd Aug 2020

Barbara, Juanita and Emma have all been diagnosed with HR+/HER2- metastatic breast cancer and have been prescribed a CDK4/6 inhibitor. Can you help us select the optimal CDK4/6 inhibitor for each of our three patients?

CDK4/6 inhibitor selection eLearning

The ‘CDK4/6 inhibitor selection’ interactive eLearning module covers the rationale for choosing one CDK4/6 inhibitor over another, for each of our three metastatic breast cancer patients.

Enrol

Section outline Content outline Time (20 mins total)
Section 1 Overview 5 mins
Section 2 Patient Case: Barbara 5 mins
  Patient Case: Juanita 5 mins
  Patient Case: Emma 5 mins

Course overview

This interactive ‘CDK4/6 inhibitor selection’ eLearning module was developed together with Dr Gregory Vidal, a medical oncologist and researcher from the West Cancer Center and Research Institute, USA. Using three example patient case studies, the module highlights the key differences between abemaciclib, palbociclib and ribociclib that may impact the choice of CDK4/6 inhibitor for your patient. Some differentiators discussed include:

  • disease characteristics (for example, central nervous system and visceral involvement)
  • patient characteristics (menopausal status and other health issues)
  • safety and tolerance (adverse events and monitoring)

System Requirements

Faculty

Dr Gregory Vidal, MD, PhD, is a Medical Oncologist at West Cancer Center and Research Institute and Assistant Professor at the University of Tennessee Health Science Center, USA. Dr Vidal trained as a clinical researcher at the University of Stanford, and the aim of his research is to discover and develop safe and effective treatments for breast cancer.

Further information

For more information on selecting the optimal CDK4/6 inhibitor for your patient, visit our pages on CDK4/6 inhibitor selection, where you will also find expert video interviews on the topic. 

CDK4/6 inhibitor selection eLearning

The ‘CDK4/6 inhibitor selection’ interactive eLearning module covers the rationale for choosing one CDK4/6 inhibitor over another, for each of our three metastatic breast cancer patients.

Enrol

Welcome: